Quaternized U50,488H ameliorates hypoxic pulmonary hypertension through PFKFB3/NLRP3 pathway

Introduction Hypoxia-induced pulmonary arterial hypertension (HPH) is a severe life-threatening disorder manifested by persistent elevation in pulmonary artery pressure and progressive right ventricular hypertrophy. Pulmonary inflammation serves as a core pathological driver contributing to pulmonary vasoconstriction and aberrant vascular remodeling during HPH progression. Methods In the present study, we aimed to evaluate the therapeutic efficacy of Q-U50,488H, a newly synthesized quaternized κ-opioid receptor (κ-OR) agonist, against HPH-associated pulmonary inflammation and further elucidate its detailed molecular mechanisms . For in vivo animal experiments, male C57BL/6 mice were were subjected to chronic‐hypoxia‐induced HPH with Q‐U50,488H and/or nor‐BNI intervention. In vitro assays were performed in primary mouse peritoneal macrophages with LPS‐induced inflammatory activation, in the presence or absence of Q‐U50,488H and nor‐BNI. Results Experimental results demonstrated that Q-U50,488H significantly alleviated pulmonary inflammation lesions in HPH mice, accompanied by diminished pulmonary macrophage infiltration, improved pulmonary vascular remodeling, and decreased right ventricular pressure and right ventricular hypertrophy index. Meanwhile, Q-U50,488H effectively inhibited the secretion of pro-inflammatory mediators including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). It also blocked the activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, and suppressed LPS-induced excessive glycolysis in macrophages. Mechanistically, the suppressive effects of Q-U50,488H on NLRP3 inflammasome activation were strictly dependent on κ-OR signaling. As a key rate-limiting glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) was confirmed to positively regulate NLRP3 inflammasome activation. Knockdown of PFKFB3 effectively inhibited NLRP3 inflammasome activity, whereas ectopic overexpression of PFKFB3 largely reversed the anti-inflammatory and metabolic regulatory effects of Q-U50,488H. Discussion In summary, Q-U50,488H represses macrophage inflammatory responses and abnormal glycolytic metabolism via regulating the κ-OR/PFKFB3 signaling axis, thereby ameliorating pulmonary inflammation and pathological vascular remodeling in HPH. This work uncovers the promising therapeutic prospect of κ-OR agonists for HPH intervention, and lays a solid mechanistic basis for the development of novel targeted anti-inflammatory strategies against hypoxic pulmonary hypertension.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-20
DOI
https://doi.org/10.3389/fphar.2026.1822763
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Quaternized U50,488H ameliorates hypoxic pulmonary hypertension through PFKFB3/NLRP3 pathway

冯娜, Juan Li, Liu Ya, Sihan Kong et al.
2 links
Frontiers in Pharmacology
Pulmonary Hypertension Research and Treatments
article

Quaternized U50,488H ameliorates hypoxic pulmonary hypertension through PFKFB3/NLRP3 pathway

冯娜, Juan Li, Liu Ya, Sihan Kong, Jianming Pei, Xiaoming Gu, Mingchao Liu, Jun Li, Jiayuan Liu, Feng Fu, Yunjuan Ren, Shumiao Zhang, Qiaojuan Wang, Guofang Lu
article en

Abstract

Introduction Hypoxia-induced pulmonary arterial hypertension (HPH) is a severe life-threatening disorder manifested by persistent elevation in pulmonary artery pressure and progressive right ventricular hypertrophy. Pulmonary inflammation serves as a core pathological driver contributing to pulmonary vasoconstriction and aberrant vascular remodeling during HPH progression. Methods In the present study, we aimed to evaluate the therapeutic efficacy of Q-U50,488H, a newly synthesized quaternized κ-opioid receptor (κ-OR) agonist, against HPH-associated pulmonary inflammation and further elucidate its detailed molecular mechanisms . For in vivo animal experiments, male C57BL/6 mice were were subjected to chronic‐hypoxia‐induced HPH with Q‐U50,488H and/or nor‐BNI intervention. In vitro assays were performed in primary mouse peritoneal macrophages with LPS‐induced inflammatory activation, in the presence or absence of Q‐U50,488H and nor‐BNI. Results Experimental results demonstrated that Q-U50,488H significantly alleviated pulmonary inflammation lesions in HPH mice, accompanied by diminished pulmonary macrophage infiltration, improved pulmonary vascular remodeling, and decreased right ventricular pressure and right ventricular hypertrophy index. Meanwhile, Q-U50,488H effectively inhibited the secretion of pro-inflammatory mediators including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). It also blocked the activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, and suppressed LPS-induced excessive glycolysis in macrophages. Mechanistically, the suppressive effects of Q-U50,488H on NLRP3 inflammasome activation were strictly dependent on κ-OR signaling. As a key rate-limiting glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) was confirmed to positively regulate NLRP3 inflammasome activation. Knockdown of PFKFB3 effectively inhibited NLRP3 inflammasome activity, whereas ectopic overexpression of PFKFB3 largely reversed the anti-inflammatory and metabolic regulatory effects of Q-U50,488H. Discussion In summary, Q-U50,488H represses macrophage inflammatory responses and abnormal glycolytic metabolism via regulating the κ-OR/PFKFB3 signaling axis, thereby ameliorating pulmonary inflammation and pathological vascular remodeling in HPH. This work uncovers the promising therapeutic prospect of κ-OR agonists for HPH intervention, and lays a solid mechanistic basis for the development of novel targeted anti-inflammatory strategies against hypoxic pulmonary hypertension.

Frontiers in PharmacologyVol. 17
National Clinical Research Center for Digestive Diseases (CN), Xijing Hospital (CN), Air Force Medical University (CN)
Fourth Military Medical University, Yakult Bio-Science Foundation, Key Research and Development Projects of Shaanxi Province
Good health and well-being
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon